Login
Companies $ANVS
$0.79 +$0.04 (4.8%) After hours
Annovis Bio, Inc. logo

Annovis Bio, Inc.

annovisbio.com

What Do They Do?

Develops buntanetap and other drug candidates for Alzheimer’s disease, Parkinson’s disease and other neurodegenerative conditions.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
  • Oct 29, 2026 NYSE notified Annovis it fell below continued listing standards Annovis plans to submit a plan to regain compliance; its stock remains listed during the cure period, subject to requirements.

Added a dementia program The latest pipeline includes buntanetap for Parkinson’s disease dementia, while the older report described the chronic-neurodegeneration program as covering Alzheimer’s and Parkinson’s diseases.

Who Do They Compete With?

Competes with Exenatide

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support